Please complete security verification This request seems a bit unusual, so we need to confirm that you're human. Please press and hold the button until it turns completely green. Thank you for your cooperation! Press and hold the button If you believe this is an error, please contact our support team. 185.149.70.50 : 8f563385-797d-44b2-ab6c-e2e50dc0
Within the last few days, careful social distancing has been overturned by demonstrations against social injustice — as thousands of Americans congregate in cities across the country protesting the death of George Floyd.The large gatherings, infectious disease experts said, could cause a catastrophic setback for controlling COVID-19 in the U.S. as cities and states try…
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f